Trial Profile
Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BLAST
- 15 Nov 2023 Results assessing systemic lupus (SLE) patients prior to treatment who will respond favorably to belimumab treatment, were presented at the ACR Convergence 2023.
- 03 Jun 2023 Results (n=24) assessing examination of gene expression variables in SLE patients prior to belimumab treatment with limited background medications in order to distinguish those who subsequently respond from those who do not, presented at the 24th Annual Congress of the European League Against Rheumatism
- 06 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.